Everce Medical is partnering with Alfresa to form a joint venture for biopharmaceutical manufacturing in Japan, marking a significant step in its globalization strategy.

Target Information

Everce Medical (永昕生醫) has announced a significant collaboration with Alfresa, a leading Japanese pharmaceutical distributor, to establish a joint venture named Alfenax Biologic Corporation. This partnership marks Everce's strategic entry into Japan's local biopharmaceutical manufacturing sector, transitioning from a regional Contract Development and Manufacturing Organization (CDMO) to a global biopharmaceutical partner. Alfresa, recognized as Japan's top prescription drug distribution group with an annual revenue exceeding 3 trillion yen (approximately NT$600 billion), is essential to the country's pharmaceutical infrastructure.

Alfresa operates in a highly concentrated and competitive Japanese pharmaceutical market. The company seeks to integrate supply chain operations at all levels, creating differentiated offerings and expanding its growth channels. This joint venture will elevate Alfresa from a pure distribution player to a supply chain integrator with biopharmaceutical manufacturing capabilities, enhancing its bargaining power and market position.

Industry Overview

The Japanese pharmaceutical industry is known for its rigour and innovation, driven by stringent government regulations and a substantial focus on research and development. The Japanese government, especially through the Ministry of Health, Labour and Welfare,